PMID- 36165073
OWN - NLM
STAT- MEDLINE
DCOM- 20221206
LR  - 20230108
IS  - 1473-5687 (Electronic)
IS  - 0954-691X (Linking)
VI  - 35
IP  - 1
DP  - 2023 Jan 1
TI  - Active smoking is associated with the development of adverse events of biological 
      therapy in patients with inflammatory bowel disease.
PG  - 15-20
LID - 10.1097/MEG.0000000000002445 [doi]
AB  - INTRODUCTION: Smoking has been associated with lower levels of anti-TNF agents, 
      higher antibodies and a reduced response to anti-TNF in patients with 
      inflammatory bowel disease (IBD). The aim of this study was to investigate the 
      possible association between smoking and adverse events (AEs) of biologics in 
      patients with IBD. MATERIAL AND METHODS: Consecutive IBD patients under biologics 
      from a prospective, longitudinal registry of a tertiary center were included. A 
      specially designed questionnaire including a wide range of AEs associated with 
      biologics was also used. RESULTS: A total of 147 patients with IBD under 
      biologics [median age (IQR) 46 (32.5-56) years, Crohn's disease (CD) 109 (74%), 
      female 51 (35%), under combination with immunosuppressants 60 (41 %), under 
      intensified biologic therapy 50 (34%), under anti-TNF 132 (89%), vedolizumab 11 
      (7.5%), ustekinumab 3 (2%)] who had completed the questionnaire forms for AEs 
      were included. There were 52 (35%) active smokers and 33 (22.5%) ex-smokers. The 
      prevalence of all AEs was 88% in smokers, 87% in ex-smokers and 79% in 
      nonsmokers. Active smoking was significantly associated with the presence of 
      arthralgias and skin rashes ( P = 0.01 and 0.002, respectively). These 
      correlations were the same for the CD and ulcerative colitis (UC), except for 
      arthralgias where there was a significant correlation only with CD ( P = 0.001). 
      There were no significant associations between smoking and other AEs ( P > 0.05). 
      CONCLUSION: Active smoking is associated with the development of dermatological 
      manifestations (both in UC and CD) and arthralgias (in CD) in IBD patients under 
      biologics.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Theodoraki, Eirini
AU  - Theodoraki E
AD  - Gastroenterology Department, University Hospital of Heraklion, Medical School, 
      University of Crete.
FAU - Orfanoudaki, Eleni
AU  - Orfanoudaki E
FAU - Petroulaki, Eleni
AU  - Petroulaki E
FAU - Foteinogiannopoulou, Kalliopi
AU  - Foteinogiannopoulou K
FAU - Koutroubakis, Ioannis E
AU  - Koutroubakis IE
LA  - eng
PT  - Journal Article
DEP - 20220912
PL  - England
TA  - Eur J Gastroenterol Hepatol
JT  - European journal of gastroenterology & hepatology
JID - 9000874
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - 0 (Biological Products)
SB  - IM
MH  - Humans
MH  - Female
MH  - Middle Aged
MH  - Prospective Studies
MH  - Tumor Necrosis Factor Inhibitors
MH  - *Colitis, Ulcerative/drug therapy/epidemiology
MH  - *Crohn Disease/therapy
MH  - *Inflammatory Bowel Diseases/drug therapy/epidemiology
MH  - Smoking/adverse effects/epidemiology
MH  - Biological Therapy
MH  - Chronic Disease
MH  - *Biological Products/adverse effects
MH  - Arthralgia
EDAT- 2022/09/28 06:00
MHDA- 2022/12/07 06:00
CRDT- 2022/09/27 05:43
PHST- 2022/09/28 06:00 [pubmed]
PHST- 2022/12/07 06:00 [medline]
PHST- 2022/09/27 05:43 [entrez]
AID - 00042737-202301000-00002 [pii]
AID - 10.1097/MEG.0000000000002445 [doi]
PST - ppublish
SO  - Eur J Gastroenterol Hepatol. 2023 Jan 1;35(1):15-20. doi: 
      10.1097/MEG.0000000000002445. Epub 2022 Sep 12.